SG11201405718QA - Anti-robo4-antibody - Google Patents

Anti-robo4-antibody

Info

Publication number
SG11201405718QA
SG11201405718QA SG11201405718QA SG11201405718QA SG11201405718QA SG 11201405718Q A SG11201405718Q A SG 11201405718QA SG 11201405718Q A SG11201405718Q A SG 11201405718QA SG 11201405718Q A SG11201405718Q A SG 11201405718QA SG 11201405718Q A SG11201405718Q A SG 11201405718QA
Authority
SG
Singapore
Prior art keywords
robo4
antibody
Prior art date
Application number
SG11201405718QA
Inventor
Yoshitaka Isumi
Toshiyuki Sato
Jun Hasegawa
Tatsuya Inoue
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP2012103929A external-priority patent/JP2013230115A/en
Priority claimed from JP2013011042A external-priority patent/JP2014141434A/en
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of SG11201405718QA publication Critical patent/SG11201405718QA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Cell Biology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
SG11201405718QA 2012-04-27 2013-04-26 Anti-robo4-antibody SG11201405718QA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2012103929A JP2013230115A (en) 2012-04-27 2012-04-27 Anti-robo4 antibody
JP2013011042A JP2014141434A (en) 2013-01-24 2013-01-24 Anti-robo4-antibody
PCT/IB2013/053312 WO2013160879A1 (en) 2012-04-27 2013-04-26 Anti-robo4-antibody

Publications (1)

Publication Number Publication Date
SG11201405718QA true SG11201405718QA (en) 2014-10-30

Family

ID=48670623

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201405718QA SG11201405718QA (en) 2012-04-27 2013-04-26 Anti-robo4-antibody

Country Status (23)

Country Link
US (2) US9683040B2 (en)
EP (1) EP2841457B1 (en)
JP (2) JP5897205B2 (en)
KR (2) KR101950898B1 (en)
CN (1) CN104768973B (en)
AU (1) AU2013254313B2 (en)
BR (1) BR112014026649A2 (en)
CA (1) CA2868074A1 (en)
CO (1) CO7111295A2 (en)
DK (1) DK2841457T3 (en)
ES (1) ES2733434T3 (en)
HK (1) HK1207093A1 (en)
IN (1) IN2014DN07799A (en)
MX (1) MX356749B (en)
MY (1) MY166821A (en)
NZ (1) NZ629291A (en)
PH (1) PH12014502382A1 (en)
PL (1) PL2841457T3 (en)
RU (1) RU2682451C2 (en)
SG (1) SG11201405718QA (en)
TW (1) TWI606065B (en)
WO (1) WO2013160879A1 (en)
ZA (1) ZA201406235B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY166821A (en) * 2012-04-27 2018-07-23 Daiichi Sankyo Co Ltd Anti-robo4-antibody
JPWO2018070390A1 (en) * 2016-10-12 2019-08-22 第一三共株式会社 Composition comprising anti-ROBO4 antibody and other agent
KR20210070643A (en) 2019-12-05 2021-06-15 김명배 self-developed wearable bridge
WO2023156437A1 (en) 2022-02-16 2023-08-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-robo4 human monoclonal antibodies and uses thereof for the treatment of cancer
CN117384290B (en) * 2023-12-11 2024-04-09 苏州因特药物研发有限公司 Human ROBO1 binding molecules and uses thereof

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
ES2139598T3 (en) 1990-07-10 2000-02-16 Medical Res Council PROCEDURES FOR THE PRODUCTION OF SPECIFIC UNION COUPLE MEMBERS.
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
WO1993006213A1 (en) 1991-09-23 1993-04-01 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5885793A (en) 1991-12-02 1999-03-23 Medical Research Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
EP0656941B1 (en) 1992-03-24 2005-06-01 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
GB9313509D0 (en) 1993-06-30 1993-08-11 Medical Res Council Chemisynthetic libraries
EP0731842A1 (en) 1993-12-03 1996-09-18 Medical Research Council Recombinant binding proteins and peptides
US6214388B1 (en) 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
US6972323B1 (en) 1997-04-01 2005-12-06 Sankyo Company, Limited Anti-Fas antibodies
ES2569919T3 (en) 1999-04-09 2016-05-13 Kyowa Hakko Kirin Co., Ltd. Procedure to control the activity of an immunofunctional molecule
CA2785941C (en) 2000-10-06 2017-01-10 Kyowa Hakko Kirin Co., Ltd. Antibody composition-producing cell
DE60127986T2 (en) * 2000-11-06 2008-01-17 Cancer Research Technology Ltd. IMAGING PROCEDURES, DIAGNOSIS AND TREATMENT OF DISEASES
JP4583638B2 (en) * 2001-03-15 2010-11-17 独立行政法人科学技術振興機構 Acetyllysine-recognizing monoclonal antibody and method for producing the same
AU2003247828B2 (en) 2002-06-27 2010-05-20 University Of Utah Research Foundation Methods and compositions for manipulating the guided navigation of endothelial tubes during angiogenesis
AU2003285500B8 (en) * 2002-11-20 2011-02-03 Cancer Research Technology Limited Antibodies binding to human magic roundabout (MR), polypeptides and uses thereof for inhibition of angiogenesis
SI1583830T1 (en) 2003-01-07 2006-12-31 Symphogen As Method for manufacturing recombinant polyclonal proteins
JP2010512327A (en) 2006-12-11 2010-04-22 ユニヴァーシティー オブ ユタ リサーチ ファウンデーション Compositions and methods for the treatment of pathological angiogenesis and vascular permeability
AU2008216495A1 (en) * 2007-02-09 2008-08-21 Genentech, Inc. Anti-Robo4 antibodies and uses therefor
TWI480050B (en) * 2009-02-10 2015-04-11 Daiichi Sankyo Co Ltd Anti-mst1r antibodies and uses thereof
MY166821A (en) * 2012-04-27 2018-07-23 Daiichi Sankyo Co Ltd Anti-robo4-antibody

Also Published As

Publication number Publication date
PH12014502382B1 (en) 2015-01-12
US20150098945A1 (en) 2015-04-09
JP6267733B2 (en) 2018-01-24
MX2014012351A (en) 2015-01-12
US9683040B2 (en) 2017-06-20
KR101950898B1 (en) 2019-02-22
PL2841457T3 (en) 2019-09-30
TWI606065B (en) 2017-11-21
CO7111295A2 (en) 2014-11-10
PH12014502382A1 (en) 2015-01-12
RU2682451C2 (en) 2019-03-19
KR20150008074A (en) 2015-01-21
US9562096B2 (en) 2017-02-07
EP2841457B1 (en) 2019-04-24
ES2733434T3 (en) 2019-11-29
EP2841457A1 (en) 2015-03-04
WO2013160879A1 (en) 2013-10-31
CN104768973A (en) 2015-07-08
IN2014DN07799A (en) 2015-05-15
MX356749B (en) 2018-06-12
HK1207093A1 (en) 2016-01-22
AU2013254313B2 (en) 2017-03-30
NZ629291A (en) 2016-09-30
MY166821A (en) 2018-07-23
CA2868074A1 (en) 2013-10-31
DK2841457T3 (en) 2019-07-22
AU2013254313A1 (en) 2014-09-18
RU2014147616A (en) 2016-06-20
JP2015515490A (en) 2015-05-28
ZA201406235B (en) 2016-07-27
TW201348257A (en) 2013-12-01
KR20190020838A (en) 2019-03-04
BR112014026649A2 (en) 2017-07-18
JP5897205B2 (en) 2016-03-30
JP2016175893A (en) 2016-10-06
CN104768973B (en) 2019-01-22
US20160108120A1 (en) 2016-04-21

Similar Documents

Publication Publication Date Title
EP2754580A4 (en) Dumptruck
DK2830816T3 (en) Hidtil ukendt coatingkoncept
EP2935220A4 (en) Peri-carbinols
EP2920142A4 (en) Methanofullerenes
HK1204445A1 (en) Surrobody cojugates surrobody
EP2812698A4 (en) Dual-acceptor time-resolved-fret
ZA201406235B (en) Anti-robo4-antibody
EP2873363A4 (en) Diopsimeter
EP2834250A4 (en) Lithiumsilicate
GB201203307D0 (en) Remvox
AU345893S (en) Treehouse
GB201205034D0 (en) Boozshooz
GB201204911D0 (en) Superswoosher
GB201204748D0 (en) Toretear
GB201204316D0 (en) Comniview
GB201204245D0 (en) MobiKey
GB201204164D0 (en) Plugstop
GB201204088D0 (en) Tidythatcable
GB201203962D0 (en) Locnlatch
GB201203844D0 (en) Salvacubo
GB201203776D0 (en) Sili-m8
GB201203815D0 (en) Mini-meals
GB201203808D0 (en) MicBooth
GB201203604D0 (en) Envelope-box
GB201203612D0 (en) Ishopfront